Targeting delivery of partial VAR2CSA peptide guided N-2-Hydroxypropyl trimethyl ammonium chloride chitosan nanoparticles for multiple cancer types

• Published in: Materials Science & Engineering C Vol. 106; p. 110171
• Main Authors: Zhao, Kai, Cheng, Guogang, Zhang, Baozhen, Li, Dan, Han, Jinyu, Chen, Jie, Wang, Baobei, Li, Mengxia, Xiao, Tianxia, Le, Aiwen, Sun, Beini, Jin, Zheng, Zhang, Jian, Fan, Xiujun
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.01.2020; Elsevier BV
• Subjects: Amino acids; Ammonium; Ammonium chloride; Anticancer properties; Binding; Biocompatibility; Cancer; Cell Line, Tumor; Chitosan; Chitosan - analogs & derivatives; Chitosan - chemistry; Choriocarcinoma; Drug Carriers - chemistry; Drug delivery; Drug delivery systems; Drug Delivery Systems - methods; Female; Humans; Male; Materials science; Multiple cancer types targeting; N-2-Hydroxypropyl trimethyl ammonium chloride chitosan; Nanoparticles; Nanoparticles - chemistry; PC-3 Cells; Peptides; Placenta; plCSA-BP; Prodigiosin; Synthesis; Xenografts; Xenotransplantation; Nanoparticles; N-2-Hydroxypropyl trimethyl ammonium chloride chitosan; Drug delivery; Multiple cancer types targeting; plCSA-BP
• ISSN: 0928-4931; 1873-0191
• DOI: 10.1016/j.msec.2019.110171

To developing a multiple cancer types targeting drug delivery carrier system, a 28 amino acids from the VAR2CSA was synthesized as the placental CSA-binding peptide (plCSA-BP). Its specific binding ability to cancer cells was tested on cancer tissue array, and the results showed that plCSA-BP could bind to multiple cancer types. Then, the plCSA-BP was used as a guiding peptide to coat nanoparticles synthesized from N-2-HACC (CSA/HACC-NPs) which were loaded with prodigiosin (CSA/HACC-PNPs) or indocyanine green (CSA/HACC-INPs). The cancer cells specific targeting and efficacy of the CSA/HACC-PNPs were tested by different cancer cells in vitro and various cancer xenograft model in vivo. A scramble peptide (SCR) was used as control and synthesized SCR/HACC-PNPs and SCR/HACC-INPs. The results showed that the CSA/HACC-INPs could specifically uptake by JEG-3, PC3 and A594 cells, and the CSA/HACC-PNPs exhibited better anti-cancer activity and lower toxic effect in subcutaneous choriocarcinoma and prostatic tumor models compared with the free prodigiosin, HACC-PNPs and SCR/HACC-PNPs. So, the CSA/HACC-NPs could be used as a specific delivery carrier for multiple cancer types, and provided an alternate treatment option of various cancers with a single recipe. [Display omitted] •Placental CSA-binding peptide (plCSA-BP), a fragment of the VAR2CSA, binds to multi-cancer types and xenografts•plCSA-BP coated nanoparticles formed by N-2-Hydroxypropyl trimethyl ammonium chloride chitosan and prodigiosin (CSA/HACC-PNPs)•In vitro cellular uptake and cell toxicity of the CSA/HACC-PNPs•Cancer cells specific targeting and efficacy of the CSA/HACC-NPs in vitro and in vivo anti-cancer activity evaluation•CSA/HACC-NPs can be an alternate universal multi-cancer targeting carrier system for chemotherapy drugs delivery.